

7. References

- Ahlenius S and Hillegaart V, Involvement of extrapyramidal motor mechanisms in the suppression of locomotor activity by antipsychotic drugs: A comparison between the effects produced by pre- and post-synaptic inhibition of dopaminergic neurotransmission, *Pharmacology, Biochemistry, and Behavior*, 24, 1409-1415, 1986.
- Alam MI, Beg S, Samad A, Baboota S, Kohli K, Ali J, Ahuja A and Akbar M, Strategy for effective brain drug delivery, *European Journal of Pharmaceutical Sciences*, 40, 385-403, 2010.
- Auclair AL, Kleven MS, Besnard J, Depoortere R and Newman-Tancredi A, Actions of novel antipsychotic agents on apomorphine-induced ppi disruption: Influence of combined serotonin 5-HT_{1A} receptor activation and dopamine d2 receptor blockade, *Neuropsychopharmacology*, 31, 1900-1909, 2006.
- Austin CA, Umbreit TH, Brown KM, Barber DS, Dair BJ, Francke-Carroll S, Feswick A, Saint-Louis MA, Hikawa H, Siebein KN and Goering PL, Distribution of silver nanoparticles in pregnant mice and developing embryos, *Nanotoxicology*, 6, 912-922, 2012.
- Baldwin CM and Scott LJ, Quetiapine extended release: In schizophrenia, *CNS Drugs*, 23, 261-269, 2009.

- Bartlett JA and van der Voort Maarschalk K, Understanding the oral mucosal absorption and resulting clinical pharmacokinetics of asenapine, *AAPS PharmSciTech*, 13, 1110-1115, 2012.
- Beloqui A, Solinis MA, Delgado A, Evora C, Isla A and Rodriguez-Gascon A, Fate of nanostructured lipid carriers (NLCs) following the oral route: Design, pharmacokinetics and biodistribution, *Journal of Microencapsulation*, 31, 1-8, 2014.
- Beloqui A, Solinís MÁ, Gascón AR, del Pozo-Rodríguez A, des Rieux A and Préat V, Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier, *Journal of Controlled Release*, 166, 115-123, 2013.
- Bishara D, Whiskey E and Taylor D, Asenapine: Novel antipsychotic for treatment of bipolar i disorder, *Future Prescriber*, 12, 5-9, 2011.
- Blasi P, Giovagnoli S, Schoubben A, Puglia C, Bonina F, Rossi C and Ricci M, Lipid nanoparticles for brain targeting i. Formulation optimization, *International Journal of Pharmaceutics*, 419, 287-295, 2011.
- Bunjes H and Unruh T, Characterization of lipid nanoparticles by differential scanning calorimetry, x-ray and neutron scattering, *Advanced Drug Delivery Reviews*, 59, 379-402, 2007.
- Carlotta M, Federica R, Patrizia NH, Donatella P, Luisa Di M and Maria C, Nose to brain delivery: New trends in amphiphile-based “soft” nanocarriers, *Current Pharmaceutical Design*, 21, 5225-5232, 2015.

- Casettari L and Illum L, Chitosan in nasal delivery systems for therapeutic drugs, *Journal of Controlled Release*, 190, 189-200, 2014.
- Chen Y and Liu L, Modern methods for delivery of drugs across the blood-brain barrier, *Advanced Drug Delivery Reviews*, 64, 640-665, 2012.
- Chiappetta DA, Hocht C, Opezzo JAW and Sosnik A, Intranasal administration of antiretroviral-loaded micelles for anatomical targeting to the brain in hiv, *Nanomedicine : Nanotechnology, Biology, and Medicine*, 8, 223-237, 2012.
- Chirio D, Gallarate M, Peira E, Battaglia L, Muntoni E, Riganti C, Biasibetti E, Capucchio MT, Valazza A, Panciani P, Lanotte M, Annovazzi L, Caldera V, Mellai M, Filice G, Corona S and Schiffer D, Positive-charged solid lipid nanoparticles as paclitaxel drug delivery system in glioblastoma treatment, *European Journal of Pharmaceutics and Biopharmaceutics*, 88, 746-758, 2014.
- Cho WS, Thielbeer F, Duffin R, Johansson EM, Megson IL, MacNee W, Bradley M and Donaldson K, Surface functionalization affects the zeta potential, coronal stability and membranolytic activity of polymeric nanoparticles, *Nanotoxicology*, 8, 202-211, 2014.
- Chopra S, Motwani SK, Iqbal Z, Talegaonkar S, Ahmad FJ and Khar RK, Optimisation of polyherbal gels for vaginal drug delivery by box-behnken statistical design, *European Journal of Pharmaceutics and Biopharmaceutics*, 67, 120-131, 2007.

- Citrome L, Asenapine for schizophrenia and bipolar disorder: A review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic, *International Journal of Clinical Practice*, 63, 1762-1784, 2009.
- Citrome L, Asenapine review, part i: Chemistry, receptor affinity profile, pharmacokinetics and metabolism, *Expert Opinion on Drug Metabolism & Toxicology*, 10, 893-903, 2014.
- Citrome L, Asenapine review, part ii: Clinical efficacy, safety and tolerability, *Expert Opinion on Drug Safety*, 13, 803-830, 2014. Cho HJ, Balakrishnan P, Chung SJ, Shim CK and Kim DD, Evaluation of protein stability and in vitro permeation of lyophilized polysaccharides-based microparticles for intranasal protein delivery, *International Journal of Pharmaceutics*, 416, 77-84, 2011.
- Costa P and Sousa Lobo JM, Modeling and comparison of dissolution profiles, *European Journal of Pharmaceutical Sciences*, 13, 123-133, 2001.
- Czapp M, Bankstahl JP, Zibell G and Potschka H, Brain penetration and anticonvulsant efficacy of intranasal phenobarbital in rats, *Epilepsia*, 49, 1142-1150, 2008.
- Das S, Ng WK and Tan RBH, Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): Development, characterizations and comparative evaluations of clotrimazole-loaded slns and nlcs?, *European Journal of Pharmaceutical Sciences*, 47, 139-151, 2012.

- De Boer T, Meulman E, Meijering H, Wieling J, Dogterom P and Lass H, Development and validation of automated spe-hplc-ms/ms methods for the quantification of asenapine, a new antipsychotic agent, and its two major metabolites in human urine, *Biomedical Chromatography : BMC*, 26, 1461-1463, 2012a.
- De Boer T, Meulman E, Meijering H, Wieling J, Dogterom P and Lass H, Quantification of asenapine and three metabolites in human plasma using liquid chromatography-tandem mass spectrometry with automated solid-phase extraction: Application to a phase i clinical trial with asenapine in healthy male subjects, *Biomedical Chromatography : BMC*, 26, 156-165, 2012b.
- Djupesland PG, Messina JC and Mahmoud RA, The nasal approach to delivering treatment for brain diseases: An anatomic, physiologic, and delivery technology overview, *Therapeutic Delivery*, 5, 709-733, 2014.
- Ema M, Kobayashi N, Naya M, Hanai S and Nakanishi J, Reproductive and developmental toxicity studies of manufactured nanomaterials, *Reproductive Toxicology (Elmsford, N.Y.)*, 30, 343-352, 2010.
- Eskandari S, Varshosaz J, Minaiyan M and Tabbakhian M, Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: In vivo pharmacodynamic studies using rat electroshock model, *International Journal of Nanomedicine*, 6, 363-371, 2011.
- Excipients HoP, Handbook of pharmaceutical excipients - 7th edition, *Pharmaceutical Development and Technology*, 18, 544-544, 2013.

- Fang CL, Al-Suwayeh SA and Fang JY, Nanostructured lipid carriers (NLCs) for drug delivery and targeting, *Recent Patents on Nanotechnology*, 7, 41-55, 2013.
- FDA, Guidance for industry Q8(R2) Pharmaceutical Development 2009 (<http://www.fda.gov/downloads/Drugs/.../Guidances/ucm073507.pdf>, Accessed on December 20, 2016).
- Franberg O, Wiker C, Marcus MM, Konradsson A, Jardemark K, Schilstrom B, Shahid M, Wong EH and Svensson TH, Asenapine, a novel psychopharmacologic agent: Preclinical evidence for clinical effects in schizophrenia, *Psychopharmacology*, 196, 417-429, 2008.
- Gartziandia O, Herran E, Pedraz JL, Carro E, Igartua M and Hernandez RM, Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration, *Colloids and Surfaces B: Biointerfaces*, 134, 304-313, 2015.
- George M, Amrutheshwar R, Rajkumar RP, Kattimani S and Dkhar SA, Newer antipsychotics and upcoming molecules for schizophrenia, *European Journal of Clinical Pharmacology*, 69, 1497-1509, 2013.
- Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P and Jeste DV, Adherence to treatment with antipsychotic medication and health care costs among medicaid beneficiaries with schizophrenia, *The American Journal of Psychiatry*, 161, 692-699, 2004.

- Han F, Li S, Yin R, Shi X and Jia Q, Investigation of nanostructured lipid carriers for transdermal delivery of flurbiprofen, *Drug Development and Industrial Pharmacy*, 34, 453-458, 2008.
- Haque S, Md S, Fazil M, Kumar M, Sahni JK, Ali J and Baboota S, Venlafaxine loaded chitosan nps for brain targeting: Pharmacokinetic and Pharmacodynamic Evaluation, *Carbohydrate polymers*, 89, 72-79, 2012.
- Hembree B, Measures of skewness and kurtosis, *e-Handbook of Statistical Methods*, (www.itl.nist.gov/div898/handbook/eda/section3/eda35b.htm, Accessed on December 20, 2016).
- Holmes LB, Teratogen-induced limb defects, *American Journal of Medical Genetics*, 112, 297-303, 2002.
- Illum L, Intranasal delivery to the central nervous system, *Blood-brain barrier in drug discovery*, John Wiley & Sons, Inc, pp. 535-565, 2015.
- Illum L, Nasal drug delivery—possibilities, problems and solutions, *Journal of Controlled Release*, 87, 187-198, 2003.
- Illum L, Transport of drugs from the nasal cavity to the central nervous system, *European Journal of Pharmaceutical Sciences*, 11, 1-18, 2000.
- Jia L, Zhang D, Li Z, Duan C, Wang Y, Feng F, Wang F, Liu Y and Zhang Q, Nanostructured lipid carriers for parenteral delivery of silybin: Biodistribution and pharmacokinetic studies, *Colloids and Surfaces. B, Biointerfaces*, 80, 213-218, 2010.

- Knudsen TB, Kavlock RJ, Daston GP, Stedman D, Hixon M and Kim JH, Developmental toxicity testing for safety assessment: New approaches and technologies, Birth Defects Research Part B, Developmental and Reproductive Toxicology, 92, 413-420, 2011.
- Kozlovskaya L, Abou-Kaoud M and Stepensky D, Quantitative analysis of drug delivery to the brain via nasal route, Journal of Controlled Release, 189, 133-140, 2014.
- Kozlovskaya L and Stepensky D, Quantitative analysis of the brain-targeted delivery of drugs and model compounds using nano-delivery systems, Journal of Controlled Release, 171, 17-23, 2013.
- Kreuter J, Nanoparticulate systems for brain delivery of drugs, Advanced Drug Delivery Reviews, 47, 65-81, 2001.
- Kuehn BM, Questionable antipsychotic prescribing remains common, despite serious risks, JAMA, 303, 1582-1584, 2010.
- Kumar M, Misra A, Babbar AK, Mishra AK, Mishra P and Pathak K, Intranasal nanoemulsion based brain targeting drug delivery system of risperidone, International Journal of Pharmaceutics, 358, 285-291, 2008.
- Landis MS, Boyden T and Pegg S, Nasal to CNS drug delivery: Where are we now and where are we heading? An industrial perspective, Therapeutic Delivery, 3, 195-208, 2012.

- Lee SJ, Min HS, Ku SH, Son S, Kwon IC, Kim SH and Kim K, Tumor-targeting glycol chitosan nanoparticles as a platform delivery carrier in cancer diagnosis and therapy, *Nanomedicine (London, England)*, 9, 1697-1713, 2014.
- Li GY, Zhong M, Zhou ZD, Zhong YD, Ding P and Huang Y, Formulation optimization of chelerythrine loaded o-carboxymethylchitosan microspheres using response surface methodology, *International Journal of Biological Macromolecules*, 49, 970-978, 2011.
- Li M, Zheng Y, Shan FY, Zhou J, Gong T and Zhang ZR, Development of ionic-complex-based nanostructured lipid carriers to improve the pharmacokinetic profiles of breviscapine, *Acta Pharmacologica Sinica*, 34, 1108-1115, 2013.
- Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J and Hsiao JK, Effectiveness of antipsychotic drugs in patients with chronic schizophrenia, *The New England Journal of Medicine*, 353, 1209-1223, 2005.
- Lochhead JJ and Thorne RG, Intranasal delivery of biologics to the central nervous system, *Advanced Drug Delivery Reviews*, 64, 614-628, 2012.
- Marston HM, Young JW, Martin FD, Serpa KA, Moore CL, Wong EH, Gold L, Meltzer LT, Azar MR, Geyer MA and Shahid M, Asenapine effects in animal models of psychosis and cognitive function, *Psychopharmacology*, 206, 699-714, 2009.
- McIntyre RS and Wong R, Asenapine: A synthesis of efficacy data in bipolar mania and schizophrenia, *Clinical Schizophrenia and Related Psychoses*, 5, 217-220, 2012.

- Md S, Haque S, Fazil M, Kumar M, Baboota S, Sahni JK and Ali J, Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: Biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method, *Expert Opinion on Drug Delivery*, 11, 827-842, 2014.
- Md S, Khan RA, Mustafa G, Chuttani K, Baboota S, Sahni JK and Ali J, Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: Pharmacodynamic, pharmacokinetic and scintigraphy study in mice model, *European Journal of Pharmaceutical Sciences*, 48, 393-405, 2013.
- Migliore MM, Vyas TK, Campbell RB, Amiji MM and Waszczak BL, Brain delivery of proteins by the intranasal route of administration: A comparison of cationic liposomes versus aqueous solution formulations, *Journal of Pharmaceutical Sciences*, 99, 1745-1761, 2010.
- Minassian A and Young JW, Evaluation of the clinical efficacy of asenapine in schizophrenia, *Expert Opinion on Pharmacotherapy*, 11, 2107-2115, 2010.
- Mistry A, Stolnik S and Illum L, Nanoparticles for direct nose to brain delivery of drugs, *International Journal of Pharmaceutics*, 379, 146-157, 2009.
- Mujtaba A, Ali M and Kohli K, Formulation of extended release cefpodoxime proxetil chitosan-alginate beads using quality by design approach, *International Journal of Biological Macromolecules*, 69, 420-429, 2014.
- Mujtaba A, Ali M and Kohli K, Statistical optimization and characterization of pH-independent extended-release drug delivery of cefpodoxime proxetil using

- box-behnen design, *Chemical Engineering Research and Design*, 92, 156-165, 2014.
- Muller RH, Radtke M and Wissing SA, Nanostructured lipid matrices for improved microencapsulation of drugs, *International Journal of Pharmaceutics*, 242, 121-128, 2002.
- NCT01244815, (<https://clinicaltrials.gov/ct2/show/results/NCT01244815>, Accessed on December 20, 2016).
- NCT01349907, <https://clinicaltrials.gov/ct2/show/NCT01349907> (Accessed on December 20, 2016).
- Nutt DJ and Attridge J, Cns drug development in europe-past progress and future challenges, *Neurobiology of Disease*, 61, 6-20, 2014.
- Pal Singh K and Tripathi N, Teratogenic potential of atypical antipsychotic drugs, quetiapine and aripiprazole in rats, *Current Psychopharmacology*, 4, 119-124, 2015.
- Pardridge WM, Drug transport across the blood-brain barrier, *Journal of Cerebral Blood Flow and Metabolism*, 32, 1959-1972, 2012.
- Patel M, Souto EB and Singh KK, Advances in brain drug targeting and delivery: Limitations and challenges of solid lipid nanoparticles, *Expert Opinion on Drug Delivery*, 10, 889-905, 2013.
- Patel S, Chavhan S, Soni H, Babbar AK, Mathur R, Mishra AK and Sawant K, Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route, *Journal of Drug Targeting*, 19, 468-474, 2011.

- Patil-Gadhe A, Kyadarkunte A, Patole M and Pokharkar V, Montelukast-loaded nanostructured lipid carriers: Part ii pulmonary drug delivery and in vitro–in vivo aerosol performance, *European Journal of Pharmaceutics and Biopharmaceutics*, 88, 169-177, 2014.
- Pauli RM, Lian JB, Mosher DF and Suttie JW, Association of congenital deficiency of multiple vitamin k-dependent coagulation factors and the phenotype of the warfarin embryopathy: Clues to the mechanism of teratogenicity of coumarin derivatives, *American Journal of Human Genetics*, 41, 566-583, 1987.
- Philbrook NA, Winn LM, Afrooz ARMN, Saleh NB and Walker VK, The effect of tio₂ and ag nanoparticles on reproduction and development of drosophila melanogaster and cd-1 mice, *Toxicology and Applied Pharmacology*, 257, 429-436, 2011.
- Piao HM, Balakrishnan P, Cho HJ, Kim H, Kim YS, Chung SJ, Shim CK and Kim DD, Preparation and evaluation of fexofenadine microemulsion for intranasal delivery, *International Journal of Pharmaceutics*, 10.1016/j.ijpharm.2010.05.0412010.
- Rahman HS, Rasedee A, How CW, Abdul AB, Zeenathul NA, Othman HH, Saeed MI and Yeap SK, Zerumbone-loaded nanostructured lipid carriers: Preparation, characterization, and antileukemic effect, *International Journal of Nanomedicine*, 8, 2769-2781, 2013.

-
- Ramalingam P and Ko YT, Enhanced oral delivery of curcumin from n-trimethyl chitosan surface-modified solid lipid nanoparticles: Pharmacokinetic and brain distribution evaluations, *Pharmaceutical Research*, 32, 389-402, 2015.
- Redhead HM, Davis SS and Illum L, Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: In vitro characterisation and in vivo evaluation, *Journal of Controlled Release*, 70, 353-363, 2001.
- Rossler W, Salize HJ, van Os J and Riecher-Rossler A, Size of burden of schizophrenia and psychotic disorders, *European Neuropsychopharmacology*, 15, 399-409, 2005.
- Saphris, US FDA label, Saphris (Asenapine) Sublingual Tablets, http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022117s017s018s019lbl.pdf, (Accessed on November 03, 2016).
- Seju U, Kumar A and Sawant KK, Development and evaluation of olanzapine-loaded plga nanoparticles for nose-to-brain delivery: *In vitro* and *in vivo* studies, *Acta Biomaterialia*, 7, 4169-4176, 2011.
- Shum L, Coleman CM, Hatakeyama Y and Tuan RS, Morphogenesis and dysmorphogenesis of the appendicular skeleton, *Birth Defects Research Part C: Embryo Today: Reviews*, 69, 102-122, 2003.
- Singh SK, Dadhania P, Vuddanda PR, Jain A, Velaga S and Singh S, Intranasal delivery of asenapine loaded nanostructured lipid carriers: Formulation,

- characterization, pharmacokinetic and behavioural assessment, *RSC Advances*, 6, 2032-2045, 2016.
- Stoner SC and Pace HA, Asenapine: A clinical review of a second-generation antipsychotic, *Clinical Therapeutics*, 34, 1023-1040, 2012.
- Suter-Zimmermann K, Transmucosal nasal drug delivery: Systemic bioavailability of nasally applied midazolam, 2008.
- Tandon R, Pharmacologic treatment of schizophrenia: Current status and future trends, *Current Psychosis & Therapeutics Reports*, 4, 40-49, 2006.
- Taratula O, Kuzmov A, Shah M, Garbuzenko OB and Minko T, Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and sirna, *Journal of Controlled Release*, 171, 349-357, 2013.
- Tarazi FI and Neill JC, The preclinical profile of asenapine: Clinical relevance for the treatment of schizophrenia and bipolar mania, *Expert Opinion on Drug Discovery*, 8, 93-103, 2013.
- Tarazi FI and Shahid M, Asenapine maleate: A new drug for the treatment of schizophrenia and bipolar mania, *Drugs of Today*, 45, 865-876, 2009.
- Thorne RG, Pronk GJ, Padmanabhan V and Frey WH, 2nd, Delivery of insulin-like growth factor-i to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration, *Neuroscience*, 127, 481-496, 2004.

-
- Tian B-C, Zhang W-J, Xu H-M, Hao M-X, Liu Y-B, Yang X-G, Pan W-S and Liu X-H, Further investigation of nanostructured lipid carriers as an ocular delivery system: In vivo transcorneal mechanism and *in vitro* release study, *Colloids and Surfaces B: Biointerfaces*, 102, 251-256, 2013.
- Tiwari R and Pathak K, Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: Comparative analysis of characteristics, pharmacokinetics and tissue uptake, *International Journal of Pharmaceutics*, 415, 232-243, 2011.
- Tollefson GD, Sanger TM, Lu Y and Thieme ME, Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol, *Archives of General Psychiatry*, 55, 250-258, 1998.
- Trapani A, Sitterberg J, Bakowsky U and Kissel T, The potential of glycol chitosan nanoparticles as carrier for low water soluble drugs, *International Journal of Pharmaceutics*, 375, 97-106, 2009.
- Turker S, Onur E and Ozer Y, Nasal route and drug delivery systems, *Pharmacy World & Science : PWS*, 26, 137-142, 2004.
- Valenstein M, Blow FC, Copeland LA, McCarthy JF, Zeber JE, Gillon L, Bingham CR and Stavenger T, Poor antipsychotic adherence among patients with schizophrenia: Medication and patient factors, *Schizophr Bull*, 30, 255-264, 2004.

- Van de Wetering-Krebbers SF, Jacobs PL, Kemperman GJ, Spaans E, Peeters PA, Delbressine LP and van Iersel ML, Metabolism and excretion of asenapine in healthy male subjects, *Drug Metabolism and Disposition*, 39, 580-590, 2011.
- Verma S, Lan Y, Gokhale R and Burgess DJ, Quality by design approach to understand the process of nanosuspension preparation, *International Journal of Pharmaceutics*, 377, 185-198, 2009.
- Wang X, Chi N and Tang X, Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting, *European Journal of Pharmaceutics and Biopharmaceutics*, 70, 735-740, 2008.
- Weiden PJ and Olfson M, Cost of relapse in schizophrenia, *Schizophrenia Bulletin*, 21, 419-429, 1995.
- Westin UE, Bostrom E, Grasjo J, Hammarlund-Udenaes M and Bjork E, Direct nose-to-brain transfer of morphine after nasal administration to rats, *Pharmaceutical Research*, 23, 565-572, 2006.
- WHO, Mental health systems in selected low- and middle-income countries: A WHO-aims cross-national analysis (http://www.who.int/mental_health/evidence/who_aims_report_final.pdf, (Accessed on December 20, 2016).
- Wilson B, Samanta MK, Santhi K, Kumar KP, Paramakrishnan N and Suresh B, Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat alzheimer's disease, *Brain Research*, 1200, 159-168, 2008.

- Wohlfart S, Gelperina S and Kreuter J, Transport of drugs across the blood-brain barrier by nanoparticles, *Journal of Controlled Release*, 161, 264-273, 2012.
- Wong HL, Wu XY and Bendayan R, Nanotechnological advances for the delivery of CNS therapeutics, *Advanced Drug Delivery Reviews*, 64, 686-700, 2012.
- Yang JP, Liu HJ, Cheng SM, Wang ZL, Cheng X, Yu HX and Liu XF, Direct transport of VEGF from the nasal cavity to brain, *Neuroscience Letters*, 449, 108-111, 2009.
- Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW and Yang CZ, Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain, *Journal of Controlled Release*, 59, 299-307, 1999.
- Yang X-y, Li Y-x, Li M, Zhang L, Feng L-x and Zhang N, Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer, *Cancer Letters*, 334, 338-345, 2013.
- Yu WJ, Son JM, Lee J, Kim SH, Lee IC, Baek HS, Shin IS, Moon C, Kim SH and Kim JC, Effects of silver nanoparticles on pregnant dams and embryo-fetal development in rats, *Nanotoxicology*, 8 Suppl 1, 85-91, 2014.
- Zeller R, The temporal dynamics of vertebrate limb development, teratogenesis and evolution, *Current Opinion in Genetics and Development*, 20, 384-390, 2010.
- Zhang P, Ling G, Pan X, Sun J, Zhang T, Pu X, Yin S and He Z, Novel nanostructured lipid-dextran sulfate hybrid carriers overcome tumor multidrug resistance of mitoxantrone hydrochloride, *Nanomedicine : Nanotechnology, Biology, and Medicine*, 8, 185-193, 2012.

Zhang Q, Jiang X, Jiang W, Lu W, Su L and Shi Z, Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain, *International Journal of Pharmaceutics*, 275, 85-96, 2004.